LyP-1 Conjugated Nanoparticles for Magnetic Resonance Imaging of Triple Negative Breast Cancer

Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging
Abedelnasser AbulrobBoguslaw Tomanek

Abstract

Triple-negative breast cancer (TNBC) does not express estrogen receptor, progesterone receptor, or Her2/neu. Both diagnosis and treatment of TNBC remain a clinical challenge. LyP-1 is a cyclic 9 amino acid peptide that can bind to breast cancer cells. The goal of this study was to design and characterize LyP-1 conjugated to fluorescent iron oxide nanoparticles (LyP-1-Fe3O4-Cy5.5) as a contrast agent for improved and specific magnetic resonance imaging (MRI) in a preclinical model of TNBC. The binding of LyP-1-Fe3O4-Cy5.5 to MDA-MB-231 TNBC cells was evaluated and compared to scrambled peptide bio-conjugated to iron oxide nanoparticles (Ctlpep-Fe3O4-Cy5.5) as a negative control. Following the in vitro study, the MDA-MB-231 cells were injected into mammary glands of nude mice. Mice were divided into two groups: control group received Ctlpep- Fe3O4-Cy5.5 and LyP-1 group received LyP-1-Fe3O4-Cy5.5 (tail vein injection at 2 mg/kg of Fe3O4). Mice were imaged with an in vivo fluorescence imager and a 9.4 T MRI system at various time points after contrast agent injection. The T2 relaxation time was measured to observe accumulation of the contrast agent in breast tumor and muscle for both targeted and non-targeted contrast agents. Immun...Continue Reading

References

Jun 8, 2002·Nature Medicine·Pirjo LaakkonenErkki Ruoslahti
Jun 16, 2004·Proceedings of the National Academy of Sciences of the United States of America·Pirjo LaakkonenErkki Ruoslahti
Oct 9, 2007·Breast Cancer Research and Treatment·David S P TanJorge S Reis-Filho
Feb 6, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cornelia LiedtkeLajos Pusztai
Oct 15, 2009·International Journal of Pharmaceutics·Guopei LuoWeiyue Lu
Mar 17, 2010·Chemical Reviews·Angelique Louie
Mar 24, 2010·AJR. American Journal of Roentgenology·Basak E DoganWei Tse Yang
Nov 12, 2010·The New England Journal of Medicine·William D FoulkesJorge S Reis-Filho
Oct 21, 2011·Neuro-oncology·Boguslaw TomanekGarnette R Sutherland
Apr 6, 2013·Scientific Reports·Arun SharmaGajendra P S Raghava

❮ Previous
Next ❯

Citations

Oct 11, 2019·Contrast Media & Molecular Imaging·Ningning SongJinhua Zhao
Mar 25, 2019·Drug Delivery·Ningning SongJinhua Zhao
Jul 14, 2019·Seminars in Cancer Biology·Balney RajithaGanji Purnachandra Nagaraju
Mar 30, 2021·Journal of Drug Targeting·Selin Seda Timur, R Neslihan Gürsoy
Feb 23, 2020·ACS Applied Materials & Interfaces·Ningning SongJinhua Zhao

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.